{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:56:16Z","timestamp":1790502976790,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010692.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000}}],"reference-count":123,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010692.pub3","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T10:02:10Z","timestamp":1469700130000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Oxycodone for neuropathic pain in adults"],"prefix":"10.1002","volume":"2016","author":[{"given":"Helen","family":"Gaskell","sequence":"first","affiliation":[{"name":"University of Oxford; Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics); Oxford Oxfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[{"name":"University of Oxford; Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics); Oxford Oxfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Stannard","sequence":"additional","affiliation":[{"name":"Frenchay Hospital; Pain Clinic, Macmillan Centre; Bristol UK BS16 1LE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"University of Oxford; Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics); Oxford Oxfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010692.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1212\/01.WNL.0000057720.36503.2C","article-title":"Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial","volume":"60","author":"Gimbel","year":"2003","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD010692.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","article-title":"Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy","volume":"105","author":"Jensen","year":"2003","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejpain.2007.12.010","article-title":"Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients","volume":"12","author":"Hanna","year":"2008","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0004|cit4","unstructured":"Mundipharma Research GmbH & Co KG (Responsible Party) An exploratory, randomised, double-blind, single-dummy, placebo controlled, parallel group study to demonstrate the analgesic efficacy of oxycodone\/naloxone prolonged release tablets in addition to pregabalin compared to pregabalin alone in opioid-na\u00efve subjects treated with pregabalin suffering from moderate to severe pain due to diabetic polyneuropathy, 2012 www.clinicaltrials.gov\/ct2\/show\/NCT00944697"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/WNL.50.6.1837","article-title":"Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia","volume":"50","author":"Watson","year":"1998","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD010692.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","article-title":"Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy","volume":"105","author":"Watson","year":"2003","journal-title":"Pain"},{"issue":"11","key":"10.1002\/14651858.CD010692.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study","volume":"11","author":"Buynak","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0008|cit8","unstructured":"EUCTR2004-003752-19-HU A randomized, double-blind, placebo- and active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone\/naloxone prolonged-release tablets in subjects with moderate to severe, chronic nonmalignant pain - OXN in moderate to severe, chronic nonmalignant pain, 2016 www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2004-003752-19-HU"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0009|cit9","unstructured":"EUCTR2005-003510-15-DE A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60 - 80 mg\/day as oxycodone\/naloxone prolonged release (OXN) compared to subjects taking oxycodone prolonged release tablets alone, 2016 www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2005-003510-15-DE"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000186502","article-title":"Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study","volume":"61","author":"Gatti","year":"2009","journal-title":"European Neurology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD010692.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.jpain.2014.01.365","article-title":"A randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of oxycodone\/ naloxone extended-release tablets (OXN) in opioid-experienced subjects with chronic low back pain","volume":"15","author":"Green","year":"2014","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0012|cit12","unstructured":"Purdue Pharma LP (Responsible Party) A randomized, double-blind, placebo-controlled, multicenter trial with an enriched study design to assess the efficacy and safety of oxycodone\/naloxone controlled-release tablets (oxn) compared to placebo in opioid-experienced subjects with moderate to severe pain due to chronic low back pain who require around-the-clock opioid therapy, 2015 www.clinicaltrials.gov\/ct2\/show\/NCT01358526"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002508-199909000-00004","article-title":"Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain","volume":"15","author":"Hale","year":"1999","journal-title":"Clinical Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpain.2004.09.005","article-title":"Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study","volume":"6","author":"Hale","year":"2005","journal-title":"Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD010692.pub3-BIB0015|cit15","first-page":"623","article-title":"Analgesic effect of oxycodone-acetaminophen tablet in treatment of backleg pain [sic]","volume":"18","author":"He","year":"2009","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0016|cit16","unstructured":"ISRCTN76170309 A randomised, crossover study of study drug 038 and controlled-release oxycodone HCl tablets in patients with chronic non-cancer pain, 2016 www.isrctn.com\/ISRCTN76170309 10.1186\/ISRCTN76170309"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jpain.2015.01.364","article-title":"Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Kopecky","year":"2015","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0018|cit18","unstructured":"Kopecky EA (Study director) A phase 3, multi-center, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of oxycodone DETERx\u2122 versus placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe chronic low back pain, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01685684"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","article-title":"Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain","volume":"27","author":"Lange","year":"2010","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1517\/14656560902796798","article-title":"Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial","volume":"10","author":"L\u00f6wenstein","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0021|cit21","unstructured":"NCT00412100 A randomised [sic], double-blind, double-dummy, parallel-group multicentre study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60-80 mg\/day as oxycodone\/naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT00412100"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0022|cit22","unstructured":"Dworkin RH (Principal investigator) Trial of analgesia with lidocaine or extended-release oxycodone for neuropathic pain treatment in multiple sclerosis (TALENT-MS), 2016 www.clinicaltrials.gov\/ct2\/show\/NCT00414453"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0023|cit23","unstructured":"NCT0049176 A study to evaluate the effectiveness and safety of tapentadol (CG5503) extended release (ER) in patients with moderate to severe chronic low back pain, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT0049176"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0024|cit24","unstructured":"NCT00784810 A double-blind, double-dummy, parallel group, randomised study to compare the efficacy & tolerability of oxycodone\/naloxone prolonged release (OXN PR) & codeine\/paracetamol in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT00784810"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0025|cit25","unstructured":"NCT01014559 Study of efficacy of OXN PR, compared to Oxy PR, for reduction of intensity of opioid-induced constipation symptoms in pts treated for cancer or non-cancer pain: a randomised, double-blind, controlled, multicentre study, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01014559"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0026|cit26","unstructured":"NCT01427270 A randomized, double-blind, double-dummy, placebo-controlled, active-controlled, parallel-group, multicenter trial of oxycodone\/naloxone controlled-release tablets (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled-release tablets (OXY)) in opioid-experienced subjects with uncontrolled moderate to severe chronic low back pain and a history of opioid-induced constipation who require around-the-clock opioid therapy, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01427270"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0027|cit27","unstructured":"NCT01427283 A randomized, double-blind, double-dummy, placebo-controlled, active-controlled, parallel-group, multicenter trial of oxycodone\/naloxone controlled-release tablets (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled-release tablets (OXY)) in opioid-experienced subjects with moderate to severe chronic low back pain and a history of opioid-induced constipation who require around-the-clock opioid therapy, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01427283"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0028|cit28","unstructured":"NCT01438567 A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation and non-inferiority in analgesic efficacy in subjects with non-malignant or malignant pain that require around-the-clock opioid therapy taking 50\/25 - 80\/40 mg twice daily as oxycodone\/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50 - 80 mg twice daily oxycodone prolonged release (OxyPR) tablets alone, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01438567"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0029|cit29","unstructured":"NCT01439100 A randomised placebo controlled study of OXN PR for severe Parkinson's disease associated pain, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01439100"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0030|cit30","unstructured":"NCT01502644 Opioid treatment for chronic low back pain and the impact of mood symptoms, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01502644"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0031|cit31","unstructured":"NCT02321397 Randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy & bowel function taking oxycodone equivalents of 120 & 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60\/30 mg PR, OXN80\/40 mg PR) BID compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT02321397"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0032|cit32","unstructured":"Simpson K (Principal investigator) A randomised, double-blind, parallel-group, multicentre study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of >20 mg\/day and <50 mg\/day as oxycodone\/naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT00412152"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1185\/03007990802584454","article-title":"Fixed-ratio combination oxycodone\/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain","volume":"24","author":"Simpson","year":"2008","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0034|cit34","unstructured":"NCT00313014 A multicenter, randomized, double-blind, active comparator study to determine the efficacy and safety of BTDS 20 or oxycodone immediate-release versus BTDS 5 in subjects with moderate to severe low back pain, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT00313014"},{"issue":"11","key":"10.1002\/14651858.CD010692.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jpain.2011.06.003","article-title":"Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study","volume":"12","author":"Steiner","year":"2011","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0036|cit36","unstructured":"NCT01971632 A randomised, double blind, placebo and active controlled, double dummy, parallel group study to determine the safety and efficacy of oxycodone\/naloxone prolonged release tablets in subjects with moderate to severe, chronic nonmalignant pain, 2016 www.clinicaltrials.gov\/ct2\/show\/NCT01971632"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jpain.2008.06.014","article-title":"Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain","volume":"9","author":"Vondrackova","year":"2008","journal-title":"Journal of Pain"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jpain.2006.05.005","article-title":"Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain","volume":"7","author":"Webster","year":"2006","journal-title":"Journal of Pain"},{"issue":"5","key":"10.1002\/14651858.CD010692.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","article-title":"Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain","volume":"10","author":"Wild","year":"2010","journal-title":"Pain Practice"},{"issue":"39","key":"10.1002\/14651858.CD010692.pub3-BIB0040|cit40","first-page":"45","article-title":"Controlled-release oxycodone - a therapeutic option for severe neuropathic pain","volume":"145","author":"W\u00f6rz","year":"2003","journal-title":"MMW Fortschritte der Medizin"},{"issue":"5","key":"10.1002\/14651858.CD010692.pub3-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jpain.2009.09.003.","article-title":"A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin","volume":"11","author":"Zin","year":"2010","journal-title":"Journal of Pain"},{"issue":"9","key":"10.1002\/14651858.CD010692.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1136\/bmj.i20","article-title":"WHO analgesic ladder: a good concept gone astray","volume":"352","author":"Ballantyne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1474-4422(11)70281-2","article-title":"Chronic pain: genes, plasticity, and phenotypes","volume":"11","author":"Baron","year":"2012","journal-title":"Lancet Neurology"},{"issue":"7","key":"10.1002\/14651858.CD010692.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/pme.12702","article-title":"Physical functioning and opioid use in patients with neuropathic pain","volume":"6","author":"Bostick","year":"2015","journal-title":"Pan Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD010692.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.amjmed.2012.12.001","article-title":"The effect of opioid therapy on endocrine function","volume":"126","author":"Brennan","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","article-title":"Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment","volume":"14","author":"Butler","year":"2013","journal-title":"Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD010692.pub3-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(12)70134-5","article-title":"The role of the immune system in the generation of neuropathic pain","volume":"11","author":"Calvo","year":"2012","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD010692.pub3-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"issue":"9","key":"10.1002\/14651858.CD010692.pub3-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010111","article-title":"Topical capsaicin (low concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007393.pub3","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD010692.pub3-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010958.pub2","article-title":"Topical lidocaine for neuropathic pain in adults","author":"Derry","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1503\/cmaj.090784","article-title":"Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone","volume":"181","author":"Dhalla","year":"2009","journal-title":"Canadian Medical Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD010692.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/j.1532-2149.2012.00282.x","article-title":"Neuropathic pain needs systematic classification","volume":"17","author":"Finnerup","year":"2013","journal-title":"European Journal of Pain"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002763.pub2","article-title":"Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults","author":"Gaskell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0062|cit62","unstructured":"McMaster University (developed by Evidence Prime, Inc.) GRADEpro Guideline Development Tool [Software]. Available from www.gradepro.org (accessed 3 March 2016) 2016"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","article-title":"Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey","volume":"52","author":"Gustorff","year":"2008","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Family Practice"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2296-14-28","article-title":"An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Family Practice"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.19","article-title":"Individualized pharmacological treatment of neuropathic pain","volume":"97","author":"Helfert","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0069|cit69","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [update March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0070|cit70","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pain.2009.09.017","article-title":"How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?","volume":"149","author":"Hoffman","year":"2010","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Jensen TS Baron R Haanp\u00e4\u00e4 M Kalso E Loeser JD Rice AS A new definition of neuropathic pain Pain 2011 2204 5 10.1016\/j.pain.2011.06.017","DOI":"10.1016\/j.pain.2011.06.017"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pain.2007.09.027","article-title":"How different is oxycodone from morphine?","volume":"132","author":"Kalso","year":"2007","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"f7339","DOI":"10.1136\/bmj.f7339","article-title":"Drugs for neuropathic pain","volume":"347","author":"Kalso","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000110284","article-title":"Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984","volume":"10","author":"Katusic","year":"1991","journal-title":"Neuroepidemiology"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub3-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/archinte.1996.00440060089011","article-title":"The importance of quality of primary studies in producing unbiased systematic reviews","volume":"156","author":"Khan","year":"1996","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5055\/jom.2013.0160","article-title":"Rationale and design of the Oxycodone Users Registry: a prospective, multicenter registry of patients with nonmalignant pain","volume":"9","author":"Kim","year":"2013","journal-title":"Journal of Opioid Management"},{"issue":"1-3","key":"10.1002\/14651858.CD010692.pub3-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pain.2009.08.023","article-title":"Incidence of facial pain in the general population","volume":"147","author":"Koopman","year":"2009","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research","volume":"107","author":"L'Abb\u00e9","year":"1987","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010692.pub3-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006146.pub2","article-title":"Opioids for neuropathic pain","author":"McNicol","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0083|cit83","volume-title":"An Evidence-Based Resource for Pain Relief","author":"McQuay","year":"1998"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0085|cit85","first-page":"15","article-title":"Managing potential publication bias","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub2","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain - establishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.pain.2010.02.032","article-title":"Chronic low back pain analgesic studies - a methodological minefield","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD010692.pub3-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.pain.2010.07.013","article-title":"Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials","volume":"151","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD010692.pub3-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.pain.2010.11.030","article-title":"Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen\/paracetamol combinations after third molar extraction","volume":"152","author":"Moore","year":"2011","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub3-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/EJA.0b013e328343c569","article-title":"Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion","volume":"28","author":"Moore","year":"2011","journal-title":"European Journal of Anaesthesiology"},{"issue":"12","key":"10.1002\/14651858.CD010692.pub3-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs\uff0d'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Moore","year":"2014","journal-title":"Pain Practice"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Moore","year":"2014","journal-title":"Pain Practice"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub3","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions - individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"European Journal of Pain"},{"issue":"8","key":"10.1002\/14651858.CD010692.pub3-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000088","article-title":"Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting","volume":"156","author":"Moore","year":"2015","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0103|cit103","unstructured":"National Institute for Health and Clinical Excellence Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013 www.nice.org.uk\/guidance\/CG173"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1526-4637.2009.00685.x","article-title":"Patient-centered perspective on treatment outcomes in chronic pain","volume":"11","author":"O'Brien","year":"2010","journal-title":"Pain Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/ACO.0b013e32832bc818","article-title":"Oxycodone: new 'old' drug","volume":"22","author":"Olkkola","year":"2009","journal-title":"Current Opinions in Anaesthesiology"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.tips.2013.02.001","article-title":"Does the pharmacology of oxycodone justify its increasing use as an analgesic?","volume":"34","author":"Olkkola","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0108|cit108","unstructured":"Cochrane Pain, Palliative and Supportive Care Group (PaPaS) author and referee guidance papas.cochrane.org\/papas-documents"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0885-3924(93)90101-Z","article-title":"A review of oxycodone's clinical pharmacokinetics and pharmacodynamics","volume":"8","author":"Poyhia","year":"1993","journal-title":"Journal of Pain & Symptom Management"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0304-3959(94)90086-8","article-title":"Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion","volume":"56","author":"Rappaport","year":"1994","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0111|cit111","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003870.pub5","article-title":"Oxycodone for cancer-related pain","author":"Schmidt-Hansen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010692.pub3-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00482-014-1455-x","article-title":"Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration","volume":"29","author":"Sommer","year":"2015","journal-title":"Schmerz"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"f5108","DOI":"10.1136\/bmj.f5108","article-title":"Opioids in the UK: what's the problem?","volume":"347","author":"Stannard","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD010692.pub3-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2125.2008.03200.x","article-title":"Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review","volume":"66","author":"Straube","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010692.pub3-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-29","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurology"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"Journal of Pain"},{"issue":"18","key":"10.1002\/14651858.CD010692.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"Hecke","year":"2014","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD010692.pub3-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuron.2012.02.008","article-title":"Deconstructing the neuropathic pain phenotype\u00a0to reveal neural mechanisms","volume":"73","author":"Hehn","year":"2012","journal-title":"Neuron"},{"issue":"9859","key":"10.1002\/14651858.CD010692.pub3-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD010692.pub3-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010567.pub2","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","author":"Wiffen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010692.pub3-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010692.pub2","article-title":"Oxycodone for neuropathic pain and fibromyalgia in adults","author":"Gaskell","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010692.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T08:17:02Z","timestamp":1693988222000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010692.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":123,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010692.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}